Golden
Arpeggio Biosciences

Arpeggio Biosciences

A a biotechnology company developing a drug-screening platform for the acceleration of drug discovery by combining custom laboratory assay and proprietary machine learning algorithms.

Arpeggio Biosciences is a biotechnology company headquartered in Boulder, Colorado that was founded in 2017 by Robin Dowell and Joey Azofeifa. Arpeggio Biosciences headquarters is located in the BioFrontiers Institute in the University of Boulder Colorado. The company is developing a drug-screening platform for the acceleration of drug discovery by combining custom laboratory assay and proprietary machine learning algorithms.

Drug screening

The companies drug screening platform can be used by scientists performing research related to drug discovery and the mechanisms of action underlying the effectiveness of drugs. The drug screening platform provides time series profiling of drug compounds using RNA-profiling technology to gain insight into how thousands of genes are interacting within the human body. The company then uses machine learning algorithms to analyze the time series profile to discover causal signalling networks, which can give researchers insight into the underlying mechanisms of action for their drugs, and help them predict how a certain drug will affect a patient. 



Timeline

Funding rounds

2 Results
Funding round
Funding round
Funding round amount (USD)
Funding round amount (USD)
Funding type
Funding type
Funding round date
Funding round date
Investment
Investment

People

Name
Role
LinkedIn

Dan Weaver

CEO



Further reading

Title
Author
Link
Type
Date









Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References